Mereo BioPharma (MREO) Accounts Payables (2017 - 2026)

Mereo BioPharma (MREO) has reported Accounts Payables for 10 consecutive years, with $3.2 million the latest figure, recorded in Q1 2026.

• Quarterly Accounts Payables rose 10.33% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (up 10.33% YoY) and the FY2025 annual result came in at $1.3 million, down 45.37% from the prior year.
• Accounts Payables advanced to $3.2 million in Q1 2026 per MREO's latest filing, from $1.3 million in the prior quarter.
• Over the last five years, Accounts Payables for MREO reached as high as $3.6 million in Q4 2022 and fell as low as $879000.0 in Q3 2025.
• A 5-year average of $2.4 million and a median of $2.4 million in 2024 frame the typical range for Accounts Payables.
• The largest YoY upside for Accounts Payables was 19.1% in 2025 against a maximum downside of 57.85% in 2025.
• Year by year, Accounts Payables stood at $3.6 million in 2022, then plunged by 35.02% to $2.3 million in 2023, then grew by 4.01% to $2.4 million in 2024, then sank by 45.37% to $1.3 million in 2025, then surged by 142.01% to $3.2 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $3.2 million, $1.3 million, and $879000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.